<?xml version="1.0" encoding="UTF-8"?>
<p>We assessed the patients for study eligibility during a 21‐day screening period. The included patients were assessed for baseline parameters on day 0. On day 1, the patients underwent THA; at the end of the procedure, they received local injections of the investigational product in accordance with their allocated group. Patients in the dosing arms received 1.5 × 10
 <sup>8</sup> (150 M group) and 3.0 × 10
 <sup>8</sup> (300 M group) PLX‐PAD cells, respectively.
</p>
